Nineteen patients who have been randomly assigned to sunitinib remained in the study for more than 1 year, in comparison with four patients who were randomly designated to placebo . The most common known reasons for study discontinuation were disease progression , termination of the trial , and adverse events . The most typical adverse events leading to discontinuation in the sunitinib group were exhaustion and diarrhea and cardiac failing . The mean relative dosage intensity was 91.3 percent in the sunitinib group and 100.6 percent in the placebo group.‘Healthcare and science jobs are powerful, meaningful, and satisfying,’ stated Dr. DiGate.’.. Heart Patients Worldwide Passing up on Key Drugs: – TUESDAY, Oct. 20, 2015 – – Many patients world-wide don’t receive generic life-saving heart medications that are supposedly affordable, a new study reveals. In poor and middle-income nations, these vital medications tend to be not widely available or are very costly. In wealthy countries, as much as half of sufferers with a history of cardiovascular disease or stroke still don’t receive them, the researchers found.